Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
AVEO PHARMACEUTICALS, INC. (AVEO) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/07/2022 8-K Quarterly results
Docs: "AVEO Oncology Reports Third Quarter 2022 Financial Results – Total Q3 2022 Net Revenue of $30.4 million, including $30.2 million of FOTIVDA® U.S. Net Product Revenue –"
08/04/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/14/2022 8-K Quarterly results
Docs: "AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results – Total 2021 Net Revenue of $42.3 Million – – FOTIVDA® U.S. Net Product Revenue of $38.9 Million since March 22, 2021 –"
11/08/2021 8-K Quarterly results
Docs: "AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update"
08/05/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "AVEO Oncology Reports Third Quarter 2020 Financial Results and Provides Business Update - U.S. Commercial Launch Preparations Underway Supporting the Tivozanib PDUFA Target Action Date of March 31, 2021 –"
08/10/2020 8-K Quarterly results
04/30/2020 8-K Quarterly results
Docs: "AVEO Oncology Reports First Quarter 2020 Financial Results and Provides Business Update"
03/16/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
05/09/2019 8-K Quarterly results
Docs: "AVEO Reports First Quarter 2019 Financial Results and Provides Business Update"
03/14/2019 8-K Quarterly results
Docs: "AVEO Reports Full Year 2018 Financial Results and Provides Business Update"
11/09/2018 8-K Quarterly results
Docs: "AVEO Reports Third Quarter 2018 Financial Results and Provides Business Update"
05/08/2018 8-K Quarterly results
Docs: "AVEO Reports First Quarter 2018 Financial Results and Provides Business Update"
03/13/2018 8-K Quarterly results
Docs: "AVEO Reports Full Year 2017 Financial Results and Provides Business Update"
11/07/2017 8-K Quarterly results
Docs: "AVEO Reports Third Quarter 2017 Financial Results and Provides Business Update"
08/09/2017 8-K Quarterly results
Docs: "SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVEO Pharmaceuticals, Inc. Date: August 9, 2017 By: /s/ Michael Bailey Michael Bailey President and Chief Executive Officer EXHIBIT INDEX Exhibit No. Description",
"AVEO Reports Second Quarter 2017 Financial Results and Provides Business Update"
05/04/2017 8-K Form 8-K - Current report
03/22/2017 8-K Form 8-K - Current report
11/04/2016 8-K Form 8-K - Current report
08/04/2016 8-K Quarterly results
Docs: "AVEO Oncology Reports Second Quarter 2016 Financial Results and Provides Business Update"
10/30/2012 8-K Quarterly results
Docs: "AVEO Announces Strategic Restructuring and Provides Third Quarter Financial Results"
08/02/2012 8-K Quarterly results
Docs: "AVEO Reports Second Quarter 2012 Financial Results"
05/03/2012 8-K Quarterly results
Docs: "AVEO Reports First Quarter 2012 Financial Results and Recent Developments",
"AVEO Announces Preliminary Results of Exploratory Phase 2 Study Evaluating HGF Inhibitor in First-Line Patients with Advanced Lung Cancer"
02/14/2012 8-K Quarterly results
Docs: "AVEO Reports 2011 Financial Results and Highlights Fourth Quarter Progress"
11/02/2011 8-K Form 8-K - Current report
07/28/2011 8-K Quarterly results
Docs: "AVEO Reports Second Quarter 2011 Accomplishments and Financial Results CAMBRIDGE, Mass., July 28, 2011 - AVEO Pharmaceuticals, Inc. today reviewed key second quarter accomplishments and reported consolidated financial results for the second quarter of 2011. “We are very pleased with the progress we have made against our corporate goals for 2011 in the first half of the year, including the initiation of our partnership with Astellas in support of tivozanib, completion of enrollment in the ongoing Phase 2 clinical trial of our HGF/c-MET pathway inhibitor, ficlatuzumab, and progress with AV-203, our anti-ErbB3 monoclonal antibody,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO. “In addition, our Human Response Platform continued to be productive, evidenced in part by the re..."
04/28/2011 8-K Form 8-K - Current report
02/16/2011 8-K Quarterly results
Docs: "Astellas and AVEO Pharmaceuticals Enter into Worldwide Agreement to Develop and Commercialize Tivozanib Outside of Asia",
"AVEO Reports 2010 Financial Results and Highlights Progress with Tivozanib and Ficlatuzumab"
11/04/2010 8-K/A Quarterly results
Docs: "AVEO Reports Third Quarter 2010 Financial Results and Recent Developments"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy